The proposed sale, valued at nearly ₹2,500 crore, has a floor price fixed at ₹860 per share, about a 5% discount to the company’s last closing price. The deal is expected to be a clean-out trade, signalling a complete exit for the investor.
Sai Life Sciences, a Hyderabad-based contract research, development, and manufacturing organisation (CRDMO), has seen strong operational momentum over the past year, reflected in both earnings and margins. In Q1FY26, the company swung to a profit after tax of ₹60 crore, compared with a loss of ₹13 crore in Q1 FY25. Revenues from operations rose 77% year-on-year to ₹496 crore, led by a 113% jump in the CDMO segment and 38% growth in Discovery revenues.
Also Read: Apollo Hospitals promoter Suneeta Reddy likely to offload partial stake via block deal: SourcesEarnings before interest, tax, depreciation and amortisation surged to ₹125 crore, with margins expanding to 25% from 11% a year ago, driven by scale efficiencies, improved productivity, and operating leverage.
Sai Life has also guided for a compound annual growth rate of 15–20% in revenues over the next three to five years, alongside a margin increase from 24% to 30%.
On Thursday, shares of Sai Life Sciences closed at ₹905.90, down 2.16% on the NSE.
(Edited by : Sheersh Kapoor)
